

Supplementary Table 2. Major clinicopathologic characteristics of patients in the PD-L1 (-/+) group

Sex/Age, yr	Pathology	EGFR	ALK	Archival tissue	Recent tissue	Interval periods, mo	Treatment during interval
Female, male/74	Squamous	NA	NA	Lung	Skin (anterior neck)	3-37	Gemcitabine plus carboplatin
Male/71	Adenocarcinoma	L858R	Negative	Lung	Lung	3-93	Gefitinib
Male/80	Squamous	NA	NA	Lung	Lymph node (cervical)	6-33	Gemcitabine plus carboplatin
Male/67	Adenocarcinoma	L858R	Negative	Lung	Lymph node (supraclavicular)	7-43	Clinical trial (olmutinib)
Male/70	Adenocarcinoma	WT	Negative	Lung	Lymph node (supraclavicular)	10-63	CCRT (paclitaxel plus carboplatin)
Female/53	Adenocarcinoma	L858R	Negative	Lung	Lymph node (mediastinal)	10-93	Gefitinib
Male/67	Adenocarcinoma	WT	Negative	Pleura	Lymph node (supraclavicular)	11-03	Pemetrexed plus cisplatin
Female/62	Adenocarcinoma	E19del	Negative	Lung	Lung	16-57	Gefitinib, pemetrexed
Male/63	Squamous	NA	NA	Lung	Lymph node (mediastinal)	17-07	CCRT (paclitaxel plus carboplatin)
Male/58	Squamous	NA	NA	Lung	Lymph node (supraclavicular)	18-03	Surgical resection, vinorelbine plus cisplatin
Male/75	Squamous	NA	NA	Lung	Liver	20-20	CCRT (paclitaxel plus carboplatin), gemcitabine plus carboplatin, radiotherapy
Male/66	Adenocarcinoma	L858R	Negative	Lung	Lung	26-40	Gemcitabine plus carboplatin, paclitaxel, radiotherapy, clinical trial (ATR inhibitor)
Female/58	Adenocarcinoma	L858R	Negative	Kidney	Lymph node (supraclavicular)	27-37	Surgical resection, gemcitabine plus carboplatin
Male/76	Mixed	WT	Negative	Lung	Lung	31-53	Bronchoscopic tumor removal
Female/71	Adenocarcinoma	E19del	Negative	Lung	Lymph node (axillary)	32-03	Gefitinib, pemetrexed
Male/69	Adenocarcinoma	WT	Positive	Lymph node (supraclavicular)	Liver	37-10	CCRT (paclitaxel plus carboplatin), crizotinib, alectinib, pemetrexed
Male/67	Adenocarcinoma	WT	Negative	Lung	Lymph node (supraclavicular)	38-00	Surgical resection
Male/73	Squamous	NA	NA	Lung	Lung	44-67	Surgical resection, paclitaxel plus carboplatin CCRT (paclitaxel plus carboplatin) gemcitabine plus carboplatin, docetaxel
Male/78	Adenocarcinoma	WT	Negative	Lung	Bone, T1-3	46-67	Surgical resection, CCRT (paclitaxel plus carboplatin)

PD-L1, programmed death-ligand 1; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NA, not applicable; WT, wild type; CCRT, concurrent chemoradiotherapy; ATR, ataxia telangiectasia and Rad3 related.